What Happened?
A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk.
As reported by CNBC, rising Treasury yields put direct, outsized pressure on long-duration assets, because higher interest rates increase the discount rate applied to future corporate earnings, thereby diminishing the present value of the distant cash flows that early-stage drug and life sciences companies rely on to justify their high valuations.
Furthermore, CNBC analysts noted that investors are increasingly reassessing the impact of these elevated interest rates on overall economic growth and corporate debt-servicing capacity, which is particularly concerning for clinical-stage healthcare firms that must continuously tap debt markets to fund research and development.
Ultimately, CNBC observed that a broader flight to safety temporarily outweighed inflation fears across the market, prompting capital to aggressively exit these riskier, high-multiple healthcare assets and flow toward the relative stability of the Treasury market and blue-chip equities.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Drug Development Inputs & Services company Azenta (NASDAQ: AZTA) fell 7.9%. Is now the time to buy Azenta? Access our full analysis report here, it’s free.
- Therapeutics company Myriad Genetics (NASDAQ: MYGN) fell 5.5%. Is now the time to buy Myriad Genetics? Access our full analysis report here, it’s free.
- Therapeutics company Moderna (NASDAQ: MRNA) fell 11.1%. Is now the time to buy Moderna? Access our full analysis report here, it’s free.
- Drug Development Inputs & Services company Repligen (NASDAQ: RGEN) fell 6.2%. Is now the time to buy Repligen? Access our full analysis report here, it’s free.
- Genomics & Sequencing company PacBio (NASDAQ: PACB) fell 13%. Is now the time to buy PacBio? Access our full analysis report here, it’s free.
Zooming In On PacBio (PACB)
PacBio’s shares are extremely volatile and have had 86 moves greater than 5% over the last year. But moves this big are rare even for PacBio and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 11 days ago when the stock gained 9.9% on the news that EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate genomic and epigenomic analysis for rare disease interpretation, incorporating data from PacBio HiFi sequencing. The partnership combines DNA methylation episignature analysis with genomic and multi-omics capabilities to advance rare-disease interpretation.
Through the agreement, EpiSign METRIC 5-base extends automated episignature analysis for over 300 disorders to Geneyx customers analyzing DNA methylation data produced by PacBio HiFi, Illumina 5-base, and Oxford Nanopore sequencing.
PacBio is down 5.7% since the beginning of the year, and at $1.74 per share, it is trading 39.5% below its 52-week high of $2.87 from October 2026. Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at only $71.43.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
